Bone Marrow Stimulation (Microfracture/Drilling)

Long-Term Survival Data (2024-2025)

→ Microfracture pokes tiny holes in bone to cause bleeding. Stem cells from bone marrow form a clot that becomes "fibrocartilage" - scar-like tissue that's not as strong as real cartilage, but can reduce pain. Like patching with duct tape instead of the original material.

2025 Systematic Review: Mid-to-Long Term Outcomes

A 2025 systematic review of 43 studies (2,721 patients, 5-24 year follow-up) found [71]:

• BMS is the most frequently used treatment for small (<1.5 cm²) primary lesions
  → BMS = Bone Marrow Stimulation; primary = first-time lesion (not a recurrence)
• Survival rates (no revision) at latest follow-up: 87.4% to 100%
• Primary lesions: 82% success rate (95% CI: 78-86%)

2025 Five-Year Follow-Up Study

A 2025 study in Indian Journal of Orthopaedics reports 5-year outcomes [72]:

• Short-term efficacy well-established; mid-to-long term outcomes remain ambiguous
• Focus on pain and functional recovery at 5 years

DGOU 2024 Guidelines

→ DGOU = German Society of Orthopedics and Traumatology (respected European guidelines)

• Debridement with BMS supported for lesions <1.0 cm² without bony defect [24]
  → Debridement = surgically cleaning out damaged/dead tissue
• For lesions >1.0 cm², additional scaffold is recommended [24]
  → Scaffold = a supportive framework (like construction scaffolding) that helps new tissue grow
• Consensus: OCLs >1.5 cm² require membrane scaffold augmentation [24]
  → OCL = Osteochondral Lesion; augmentation = adding something to enhance the procedure

Cystic Lesions (2025 Meta-Analysis)

A 2025 meta-analysis found no clinical difference between simple and cystic lesions if cyst depth <5-6mm, medial talus location, and patient <40 years old [26].

→ Cystic lesion = has a fluid-filled hole in the bone; simple = just cartilage damage without a bone cyst

However, for large cystic OLT (>300 mm³), autologous osteochondral transfer showed superior survival vs BMS (p=0.042) [27].

→ Autologous = using tissue from your own body (from another location)

2026 CARTILAGE Meta-Analysis: Lower Repair-Tissue Quality After BMS

A meta-analysis of second-look arthroscopy studies found lower repair-tissue quality after BMS than fixation, osteochondral transplantation, or cartilage implantation [169]:

→ This measures how repair tissue looked during a later arthroscopy. It does not prove that patient-reported outcomes are worse, and it did not directly study a post-allograft lesion.

2026: Immediate Weightbearing After BMS Appears Safe

A matched cohort study found no significant difference in outcomes between immediate and delayed weightbearing after arthroscopic BMS at 12 months [170]. This may simplify post-op protocols.

Long-term Concerns

Fibrocartilaginous repair tissue tends to degenerate over time. Good clinical outcomes at midterm, but radiological outcomes showed repair tissue surface damage [20]. This may be a harbinger for long-term problems [28].

→ Fibrocartilaginous = scar-like cartilage (weaker than original hyaline cartilage); harbinger = warning sign

Added August 3, 2026 — a 2026 Level 1 trial that refused to enroll this lesion, and said why

→ The strongest evidence against marrow stimulation here does not come from a study showing it failed. It comes from a study that would not let him in.

A randomized controlled trial compared a precision micro-drilling technique against conventional microfracture in 56 patients with two-year follow-up [318]. The result itself is modest: better sport scores at three and six months, then “after 12 months, there was no significant difference in clinical outcomes between the two groups.” The technique is not available outside China.

The eligibility criteria are the finding. Enrollment required “the diameter of OLTs smaller than 10 mm, the size of OLTs smaller than 100 mm², and the depth of OLTs smaller than 5 mm,” and excluded “large cystic OLTs… history of surgeries… in the same lower extremity.” This lesion — 15 mm, roughly 150 mm², cystic, revision — fails four of those at once. Enrolled lesions averaged 59–64 mm², under half its size.

And the authors give their reason in the paper: “OLTs larger than 100 mm² or those associated with large cysts (which usually increase lesion depth to larger than 5 mm) have a low success rate with BMS and generally require more aggressive treatments such as autologous osteochondral transplantation or autologous osteoperiosteal transplantation. Therefore, these patients were not included in the present study.” That is a 2026 trial team with an academic stake in a marrow-stimulation device independently restating the 2018 consensus Grade A1 statement recorded on this site — and declining to enroll this phenotype at all.

Added August 3, 2026 — medial and cystic is the worst combination for this operation

Two cohort studies, new to this site, narrow the picture to this exact lesion. A matched comparison of 31 medial against 31 lateral cystic talar lesions found medial lesions did significantly worse after marrow stimulation: less improvement in daily-life and sport scores (P = .034, P < .001), lower repair-tissue scores, and a post-operative cyst rate of 45.2% versus 16.1% (P = .013). On the sport score, only 51.6% of medial patients exceeded the minimum clinically important difference, against 80.6% of lateral [320]. This lesion is medial and cystic.

A companion study of 82 patients identified thresholds beyond which outcomes after marrow stimulation deteriorate: area 90.9 mm², depth 7.56 mm, volume 428 mm³ [321]. At ~150 mm² this lesion is 65% past the area threshold — but read that carefully: the study enrolled only lesions under 100 mm², so the cutoff is extrapolated to him rather than measured on him.

→ Two honest discounts. Both studies are Level III and retrospective, and all three of these findings come from the same institution, which is a real independence problem. They do not prove what would happen to this ankle. What they do is describe what the MASCOT trial's comparator arm is likely to deliver for this specific phenotype — which is a question for the consent conversation, not a reason to avoid the trial.

Added September 17, 2026 — the ten-year view arrives: age grades the result, and two preoperative numbers predict who fails

→ This page’s evidence against marrow stimulation for this lesion has mostly been two-year evidence. A Beijing group has now followed 103 patients for more than a decade after the operation — and the news is layered. The good: improvements held past ten years in every age group. The graded: patients under 30 did far better than everyone else, and over-45s did worst on every measure. The useful: in the older group, two numbers measured before surgery predicted who would fail to reach a meaningful quality-of-life improvement — having had symptoms longer than about two years, and bone-swelling (marrow edema) reaching deeper than about a centimeter into the talus. One of those numbers is a clock that is running on this ankle right now.

The cohort, from Peking University Third Hospital in Arthroscopy [482]: 103 marrow-stimulation patients (lesions under 150 mm², 2009–2015), minimum ten-year follow-up (mean 11.8 years), stratified by age. Under-30s reached FAOS-QoL 91 and AOFAS 92; quality-of-life MCID achievement fell stepwise from 96.7% under 30, to 70.3% at 30–45, to 52.8% over 45. In the over-45s, preoperative symptom duration >25.5 months (AUC 0.788) and baseline bone-marrow-edema depth >10.5 mm (AUC 0.772) were the thresholds predicting failure.

Read it against this ankle honestly, in both directions. Favorable: at ~30, this ankle’s owner sits at the edge of the best-performing band, and the current symptom episode (~18 months since March 2025) is still under the duration threshold — though that threshold was derived in the over-45 subgroup and travels here only as analogy. Unfavorable, and familiar: these were small primary lesions — under 150 mm², uncomplicated enough for marrow stimulation to be indicated at all — not large cystic revision lesions, which the same institution’s own trial team excluded from BMS outright ([318], above). The marrow-edema-depth threshold is the transferable piece: the September MRI documents “marrow edema-like signal” with extensive cysts but no depth number, and depth-of-edema is exactly the kind of measurement the planned CT-and-MRI review can put a millimeter value on. Third Peking University Third Hospital cohort on this site’s marrow-stimulation ledger ([320], [321]) — the single-institution caveat stands. What ten-year data changes: the argument against BMS here was never that it fails everyone; it is that this phenotype was excluded from its successes — and the decade-long durability in young, small-lesion patients sharpens rather than softens that boundary.